Search results for "MAb"
showing 10 items of 1716 documents
Smart camera based on an Embedded HW/SW Co-Processor
2008
Abstract This paper describes an image acquisition and a processing system based on a new coprocessor architecture designed for CMOS sensor imaging. The system exploits the full potential CMOS selective access imaging technology because the coprocessor unit is integrated into the image acquisition loop. The acquisition and coprocessing architecture are compatible with the majority of CMOS sensors. It enables the dynamic selection of a wide variety of acquisition modes as well as the reconfiguration and implementation of high-performance image preprocessing algorithms (calibration, filtering, denoising, binarization, pattern recognition). Furthermore, the processing and data transfer, from t…
FPGA-based concurrent watchdog for real-time control systems
2003
A straightforward and efficient implementation of a custom concurrent watchdog processor for real-time control systems is presented. Emphasis is given to the techniques used for on-line checking the main processor activity without adding overhead, and to the advantages of a field programmable gate array implementation.
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
2020
Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…
High performance hardware correlation coefficient assessment using programmable logic for ECG signals
2003
Abstract Correlation coefficient is frequently used to obtain cardiac rhythm by peak estimation and appreciate differences in the signal compared to a pattern. This work focuses on the description of a real-time correlation assessment procedure. Applied to electrocardiogram (ECG) signals, a new correlation value is obtained every new sample and pulse detection information is provided. The ECG pattern is internally stored and can be changed when desired. This procedure is useful in Systems on Chip implementation and can be applied to design compact ECG monitoring systems consisting on a system on chip where programmable logic offloads the main processor. A Xilinx FPGA device has been used fo…
Occult Hepatitis B and Infliximab-induced HBV Reactivation
2007
Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study
2006
Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX…
The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases
2010
Splenic tuberculosis in a patient with Crohn's disease on infliximab: Case report
2010
P717 Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results
2020
Abstract Background Ustekinumab is approved in Europe for the treatment of moderate-to-severe Crohn’s disease (CD) since 2016. Italian real-life data on efficacy and safety are scarce. The aim of this study was to assess effectiveness, safety and usage of Ustekinumab in an Italian cohort of patients. Methods Data of patients with moderate-to-severe CD who started Ustekinumab in Sicily were extracted from the database of the SN-IBD. Demographic data, disease-related data (disease duration, location, clinical activity) and previous therapies with biologics were collected. The primary study endpoints were steroid-free clinical remission and steroid-free clinical response at week 12, 24 and 52 …